May 9, 2023
NHIA applauds the guidance issued by FDA to allow for decentralized clinical trials, including in patients’ homes. NHIA first commented on this topic to CMS in our letter regarding the National Coverage Analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease on Jan. 11, 2022, which would have limited studies to hospital outpatient settings. As NHIA noted in its letter, during the COVID-19 public health emergency, several manufacturers successfully conducted clinical trials in remote settings, including patients’ homes.
NHIA believes that allowing decentralized clinical trials will improve the representation of a wider range of patients in trials. According to the FDA guidance, “remote clinical trial visits and clinical trial-related activities are important strategies to make trials more convenient and more accessible” and “sponsors should strive for diversity and inclusiveness in trial populations.”
The FDA also shares guidance for enabling in-person visits and trial-related activities to be provided by HCPs close to trial participants’ homes but are not a part of the trial personnel as well as collecting informed consent remotely.
The National Home Infusion Association (NHIA) is pleased to announce that Greg LoPresti, CEO Upstate HomeCare has been named Chair of its Board of Directors. LoPresti will lead the trade association representing companies that provide medically necessary infusion therapies to patients in alternate sites, as well as companies that manufacture and supply infusion and specialty pharmacy products.
Last week concluded the 2025 National Home Infusion Association Annual Conference (NHIA 2025), which brings together 1,600 home and alternate site infusion professionals for four days of networking, education, and exhibits. This year’s event saw significant growth in individuals investing to attend the event and the expo featured 150 companies displaying the latest products and services supporting the industry.
The National Home Infusion Foundation (NHIF) is proud to announce that the recipient of the 2025 Outstanding Abstract Achievement Award (OAAA) is Leslie Myers, PharmD, IgCP of CSI Pharmacy.
